Trump-Inspired World Liberty Financial Closes $550 Million Across Token Sales
WLFI completes second set of WLFI governance token sales
World Liberty Financial, Inc. (“WLFI”), the developer of a pioneering DeFi protocol and governance platform inspired by Donald J. Trump, has made history with the completion of the second set of its token sales, totaling $550 million in gross proceeds in concurrent U.S. and non-U.S. token offerings.
After launching on October 15, 2024, WLFI has successfully concluded two sets of token sales in concurrent U.S. and non-U.S. offerings. In the first set, $300 million USD of WLFI tokens were sold between the offerings, and in the second set, $250 million USD of WLFI tokens were sold between the offerings. Between all the offerings, $550 million USD in WLFI tokens have been sold.
More than 85,000 total participants in the token sales underwent Know Your Customer (KYC) process to determine participation eligibility.
"This milestone proves that those who truly understand crypto and finance recognize what we’re building — and that WLFI is on track to supercharge DeFi as it transforms global finance in the coming years," said Zach Witkoff, WLFI co-founder. "World Liberty Financial is grateful to WLFI’s early supporters and partners who saw the game-changing potential of this project and we look forward to their continued participation in the governance of the WLFI protocol. The token sales are just the beginning. We’re gearing up to launch a wave of disruptive technology that will redefine the boundaries of what’s possible with digital assets."
Over the last six months, WLFI has established key relationships with leading blockchain protocols and institutions including Ondo Finance, Ethena, Chainlink, Sui and Aave. These relationships have positioned WLFI to more rapidly build and deploy its upcoming platform which is being purpose-built to democratize finance for millions.
WLFI’s “Macro Strategy” has also assembled a variety of digital assets in its strategic reserve program including BTC, ETH, TRX, LINK, SUI, and ONDO tokens. The WLFI strategic reserve helps strengthen leading cryptocurrency projects while providing stability to its treasury through diversification before ultimate disposition. The Macro Strategy may be used in part to enable WLFI to fund innovative projects, support ecosystem growth, and create new opportunities within the rapidly evolving DeFi landscape.
WLFI remains committed to advancing its mission to create a more inclusive financial future, backed by strategic partnerships, innovative technologies and a dedicated community. As World Liberty Financial continues to build the future of decentralized finance, stay updated on the latest developments and announcements by following us on X at https://x.com/worldlibertyfi.
About World Liberty Financial
World Liberty Financial (WLFI) is a pioneering decentralized finance (DeFi) protocol and governance platform dedicated to empowering individuals through transparent, accessible, and secure financial solutions. Inspired by the vision of President Donald J. Trump, WLFI seeks to democratize access to DeFi by creating user-friendly tools that bring the benefits of decentralized finance to a broader audience. WLFI plans to be at the forefront of DeFi, offering an intuitive, robust platform that empowers users to participate actively in the financial future.
This communication includes forward looking information about future plans, predictions and expectations that are subject to risks and uncertainties and that may be subject to change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317855322/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy18.3.2025 07:00:00 CET | Press release
Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc. under the name VERSANT HCV Genotype 2.0, is a line probe assay, for in vitro diagnostic use, designed for the qualitative detection and identification of Hepatitis C virus (HCV) genotypes 1 to 6 and subtypes a and b of genotype 1 in human serum or EDTA plasma samples. Additional subtype information is available in a majority of cases. “At Fujirebio we have been pioneering molecular testing solutions since the 1990’s with our high quality LiPA platform,” says Christiaan De Wilde, CEO at Fujirebio Europe. “The historical VERSANT HCV Genotype 2.0 Assay (LiPA) served as an efficient aid to personalized HCV therapy, and we are very pleased to maintain the availability of the test, now officially a part of our INNO-LiPA product range. We would like to extend our gratitude to all INNO-LiPA customers for their continued trust.”
Protembis Announces Formation of New Scientific Advisory Board Comprised of World-Renowned Structural Heart Experts18.3.2025 07:00:00 CET | Press release
Dr. Martin Leon to Chair the New Scientific Advisory Board (SAB) of Protembis which will also include Dr Anita Asgar, Dr Samir Kapadia and Dr Nicolas van Mieghem Protembis, a privately-held emerging cardiovascular medical device company, announced today the establishment of a Scientific Advisory Board (SAB) to provide objective advice and contribute to the strategic plans of the company. Specifically, the SAB will provide overarching scientific and clinical strategic guidance, advise on emerging trends and opportunities, and provide expert counsel on scientific and clinical matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317149296/en/ The SAB will be comprised of four internationally recognized interventional cardiologists, who have made significant contributions to the understanding of the role for cerebral embolic protection (CEP) in transcatheter aortic valve replacement (TAVR): Dr Martin Leon MD, Dr Anita Asga
Mark Wiseman appointed Chairman of Alter Domus18.3.2025 06:00:00 CET | Press release
Former Chairman of BlackRock’s Alternatives Business and Global Head of Active Equities, and President & CEO of CPPIB joins leading private markets fund servicer The appointment of Mr. Wiseman underscores Alter Domus’ position as the world’s premier global alternative asset servicer Alter Domus, the leading global provider of tech-enabled fund services for the private equity, real assets and private debt sectors today appointed Mark Wiseman as Chairman. Mr. Wiseman is the former Head of Active Equities and Chairman of BlackRock’s Alternatives Business, as well as President & CEO of Canada Pension Plan Investment Board (CPPIB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317232851/en/ Mark Wiseman Following a successful tenure, René Beltjens will step down as Chairman but will retain his seat on the Board. As alternatives specialists, with $3 trillion assets under administration (AUA), Alter Domus’ end-to-end servicing
Brisbane Airport embraces advanced analytics from Cirium Sky Warehouse17.3.2025 23:00:00 CET | Press release
Queensland’s major airport pioneers data consolidation in the cloud to drive operational efficiency Brisbane Airport (BNE), which serves as the major gateway to Queensland, has partnered with aviation analytics firm, Cirium, to become one of the first airports to integrate Cirium Sky Warehouse, a data-driven cloud platform, into its modernisation efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317052819/en/ Brisbane Airport Cirium’s advanced data and analytics will be seamlessly integrated with Brisbane Airport’s business systems. This integration will support enhanced capacity planning, resource allocation, and operations analysis. Jeremy Bowen, Cirium CEO, commented: "We are delighted to support Brisbane Airport’s transformative investment to revolutionise its passenger experience and meet future travel demand. “Integrating Cirium data and analytics through the Cirium Sky Warehouse will help the airport to conso
RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product17.3.2025 20:28:00 CET | Press release
The Company Received Approval in Multiple European Countries to Initiate this Key Study Necessary for Commercial Product Approval RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental implant stabilization product. The successful completion of this pivotal clinical trial will result in the CE marking approval for the product, which will allow the company to begin commercial sales in Europe. As of the date of this press release, the company has already enrolled 30 of an expected 75 patients in this clinical trial. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306978603/en/ RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege. “The results from th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom